Long-Term Study to Evaluate the Safety and Efficacy in Participants With Primary Biliary Cholangitis of Saroglitazar Magnesium-V on Clinical Outcomes

NCT07216235 · clinicaltrials.gov ↗

PHASE3

Phase

NOT_YET_RECRUITING

Status

386

Enrollment

INDUSTRY

Sponsor class

Conditions

Primary Biliary Cholangitis

Interventions

DRUG: Saroglitazar magnesium 1 mg
DRUG: Placebo

Sponsor

Zydus Therapeutics Inc.